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The economic burden of bronchiectasis –
known and unknown: a systematic review
Pieter C. Goeminne1†, Francisco Hernandez2†, Roland Diel3, Anna Filonenko4, Rowena Hughes5, Fabian Juelich6,
George M. Solomon7, Alex Upton8, Kamonthip Wichmann4, Weiwei Xu2 and James D. Chalmers9*
Abstract
Background: The increasing prevalence and recognition of bronchiectasis in clinical practice necessitates a better
understanding of the economic disease burden to improve the management and achieve better clinical and
economic outcomes. This study aimed to assess the economic burden of bronchiectasis based on a review of
published literature.
Methods: A systematic literature review was conducted using MEDLINE, Embase, EconLit and Cochrane databases
to identify publications (1 January 2001 to 31 December 2016) on the economic burden of bronchiectasis in adults.
Results: A total of 26 publications were identified that reported resource use and costs associated with management of
bronchiectasis. Two US studies reported annual incremental costs of bronchiectasis versus matched controls of US$5681
and US$2319 per patient. Twenty-four studies reported on hospitalization rates or duration of hospitalization for patients
with bronchiectasis. Mean annual hospitalization rates per patient, reported in six studies, ranged from 0.3–1.3, while
mean annual age-adjusted hospitalization rates, reported in four studies, ranged from 1.8–25.7 per 100,000 population.
The average duration of hospitalization, reported in 12 studies, ranged from 2 to 17 days. Eight publications reported
management costs of bronchiectasis. Total annual management costs of €3515 and €4672 per patient were reported in
two Spanish studies. Two US studies reported total costs of approximately US$26,000 in patients without exacerbations,
increasing to US$36,00–37,000 in patients with exacerbations. Similarly, a Spanish study reported higher total annual costs
for patients with > 2 exacerbations per year (€7520) compared with those without exacerbations (€3892). P. aeruginosa
infection increased management costs by US$31,551 to US$56,499, as reported in two US studies, with hospitalization
being the main cost driver.
Conclusions: The current literature suggests that the economic burden of bronchiectasis in society is significant.
Hospitalization costs are the major driver behind these costs, especially in patients with frequent exacerbations. However,
the true economic burden of bronchiectasis is likely to be underestimated because most studies were retrospective, used
ICD-9-CM coding to identify patients, and often ignored outpatient burden and cost. We present a conceptual framework
to facilitate a more comprehensive assessment of the true burden of bronchiectasis for individuals, healthcare systems
and society.
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Background
Patients with non-cystic fibrosis bronchiectasis experi-
ence daily respiratory symptoms, such as chronic
cough, sputum production, and exacerbations [1].
These symptoms cause significant morbidity, reducing
physical performance, and severely affecting a patient’s
health-related quality of life (HRQoL). Improving the
quality of care for patients with bronchiectasis is para-
mount in limiting the impact of disease burden on daily
functioning [2].
Management of bronchiectasis aims to control symp-
toms, reduce the incidence of exacerbations, and prevent
disease progression. This is achieved through a multifa-
ceted approach that includes airway clearance therapies,
such as physiotherapy and/or exercise, antibiotic ther-
apy, and anti-inflammatory treatment [1, 3–6]. In
addition, hospitalization and antibiotic treatment may be
required for the management of exacerbations. For these
reasons, care is provided in both primary and secondary
settings, and the provision of care may shift between
these settings over the course of the disease. Indeed, the
structure and intensity of healthcare resource use for the
management of bronchiectasis may vary across different
settings.
Although non-cystic fibrosis bronchiectasis has been a
neglected disease, its apparent prevalence is increasing
[7, 8], possibly reflecting improved diagnosis through
greater use of high-resolution computed tomography
(HRCT) of the chest [1, 3]. With the rising number of
patients requiring appropriate management, a better un-
derstanding of the current economic disease burden of
bronchiectasis is needed to ensure efficient allocation of
healthcare resources. Therefore, the aim of this system-
atic literature review was to identify literature reporting
resource use and costs associated with the management
of bronchiectasis in adults, and to identify knowledge
gaps. Based on the findings, we present a conceptual
framework to facilitate a more comprehensive assess-
ment of the true burden of bronchiectasis for individ-
uals, healthcare systems, and society.
Methods
A systematic literature review was conducted using
MEDLINE, Embase, EconLit, and the Cochrane data-
bases (Cochrane Database of Systematic Reviews, Data-
base of Abstracts of Reviews of Effects, Cochrane
Central Register of Controlled Trials, Health Technology
Assessments Database, NHS Economic Evaluation Data-
base, Cochrane Airways Group). The search aimed to
identify publications reporting the economic and hu-
manistic burden of bronchiectasis in adults. Searches in-
cluded terms for bronchiectasis and terms relating to
resource use, costs, cost-effectiveness and health-related
quality of life (HRQoL).
The research covered the period from 1 January 2001
to 20 October 2015, and an update was carried out
from 1 September 2015 to 31 December 2016. Searches
were also performed to identify relevant abstracts pre-
sented at the following congresses (from October 2012
to January 2017): the European Respiratory Society, the
Interscience Conference of Antimicrobial Agents and
Chemotherapy, the European Congress of Clinical
Microbiology and Infectious Diseases, the Infectious
Disease Society of America (IDWeek), the British Thor-
acic Society, the International Society for Pharmacoeco-
nomics and Outcomes Research, the American College
of Chest Physicians (CHEST), and the First World
Bronchiectasis Conference.
All electronic databases and congress searches under-
went double-blind screening of the title and abstract by
two researchers. Eligibility criteria included publications
that reported costs, cost savings, and resource use in
adults with bronchiectasis. Publications were excluded if
they were in languages other English; reviews, editorials,
notes and letters were also excluded. An example search
string is included in Additional file 1. Selected articles
underwent a full-text review to verify quality and eligibility.
A random selection of excluded articles was reviewed by an
independent researcher for quality-control purposes. Dis-
crepancies between reviewers were discussed and amended.
All data were extracted into pre-defined data extrac-
tion grid by a single researcher. A second researcher in-
dependently checked all data. (See Additional file 2 for
an example extraction grid).
Results
A total of 26 publications were identified reporting re-
source use and costs associated with the management of
adults with bronchiectasis (see Fig. 1). One study identi-
fied as an abstract in the systematic review has subse-
quently been published as a full paper [9]. Fifteen
studies included > 200 patients; of these, six were con-
ducted in the USA [9–14], three in the UK [15–17], two
in Spain [18, 19], and the others in New Zealand [20],
Germany [21], Poland [22], and Singapore [23]. All stud-
ies involved adults and one included children [20] and a
second included individuals of any age. [21] Most studies
described in full papers reported on the presence of co-
morbidities, including cardiovascular disease, COPD,
diabetes, respiratory disease, primary hypertension or re-
ported a Charlson comorbidity index score, suggesting
that many patients had comorbidities. Some comparative
studies adjusted for comorbidities whereas others do not
provide this level of detail in their description of the
methodology used.
Resource use in the management of bronchiectasis
was described in 24 studies. The following resource use
items, indexed by setting, were reported:
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 Inpatient care: hospital admission, including
intensive care unit (ICU) and emergency room (ER)
visits.
 Outpatient care: primary and secondary care visits,
diagnostics (including an initial chest CT scan, blood
tests, immunology tests, lung function tests) and/or
monitoring by HRCT and microbiology, respiratory
physiotherapy, and airway clearance techniques.
 Medication and other treatments: antibiotics,
bronchodilators, corticosteroids, oxygen therapy.
Two US studies compared the resource use and costs
for patients with bronchiectasis versus matched controls
without bronchiectasis and provide an estimate of the in-
cremental resource use and costs due to bronchiectasis.
[12, 14]. Twenty-two further studies reported on
hospitalization rates or length of stay for patients with
bronchiectasis; [9, 11, 13–22, 24–33] some of these studies
also reported on other aspects of resource use. Eight
studies report the costs of managing bronchiectasis and
provide evidence for cost drivers in this disease. [9, 10, 12,
14, 18, 19, 34, 35]
Incremental resource use and cost due to bronchiectasis
Bronchiectasis is associated with increases in resource
use and overall management costs compared with indi-
viduals without bronchiectasis, as demonstrated in two
US studies. Weycker et al. performed a detailed evalu-
ation of the costs of bronchiectasis based on an analysis
of US claims during a 3-year period from January 1999
onwards [14]. Patients with bronchiectasis (n = 1424)
were identified through ICD-9-CM codes and data col-
lected included hospital admissions, outpatient visits,
and prescription medications. Costs for patients with
bronchiectasis were compared with matched controls
within the claims database without bronchiectasis on the
basis of age, sex, geographic region, and selected comor-
bid conditions. Compared with the controls, patients
Fig. 1 PRISMA flow diagram. Reasons for exclusion of articles from the initial search from inclusion in the report (n = 12): relevant data not
reported or very limited (n = 4), patient population not specifically bronchiectasis (n = 5), and duplicate (full paper identified in the update search,
n = 3). Reasons for exclusion of articles from the updated search: relevant data not reported or very limited (n = 5). The updated search identified
economic and HRQoL studies but was only screened to identify economic articles
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with bronchiectasis had on average longer hospitals stays
(4.5 days vs 2.5 days), a greater number of admissions
(0.6 vs 0.4), more outpatient encounters (20.1 vs 14.0),
and more days of antibiotic, corticosteroid, and bron-
chodilator use (27.2, 12.2, and 4.5, respectively). In-
creased resource use resulted in an additional annual
increment of US$5681 (95% CI US$4862–6593) com-
pared with controls. Inpatient care accounted for 56% of
the increase in costs; outpatient visits (16%) and out-
patient prescriptions (18%) accounted for most of the re-
mainder of the increased costs.
A more recent US MarketScan database analysis ex-
amined the increase in resource use and costs for pa-
tients with bronchiectasis during the first year after
diagnosis [12]. Data were analyzed for a 5-year period
from 2005 for patients diagnosed with bronchiectasis
(n = 9146) and matched controls (without bronchiec-
tasis) (n = 27,438). This study reported an annual in-
cremental burden for patients with bronchiectasis vs
controls of 2.0 more outpatient visits, 0.4 more ER
visits, and 2.4 more pharmacy scripts (all p < 0.001).
No increase in hospital admissions was observed.
When only considering respiratory-related resource
utilization, patients with bronchiectasis had 1.6 more
outpatient visits, 0.3 more ER visits, and 0.4 more
pharmacy scripts than controls (all p < 0.001). This re-
sulted in an increase of US$2319 overall and
US$1607 for respiratory-related costs for the first year
after diagnosis.
Hospitalization and other resource use
Twenty-two further studies reported hospitalization
rates and/or the length of hospital stay in patients with
bronchiectasis, likely reflecting management of severe
exacerbations. Four studies used national databases in
the USA (1993–2006), Germany (2005–2011), Spain
(2004–2013), and New Zealand (2008–2013) to deter-
mine mean annual age-adjusted hospitalization rates for
bronchiectasis as the primary diagnosis. Rates ranged
from 1.8 to 25.7 per 100,000 population (Table 1) [13,
18, 20, 21]. In addition, two studies reported rates for
bronchiectasis as any diagnosis; these rates were consid-
erably higher (e.g., 9.4 vs 1.8 per 100,000 for Germany
[21]) compared with those studies reporting rates of
bronchiectasis as a primary diagnosis. Another six stud-
ies have reported mean annual hospitalization rates per
patient in specific cohorts; values ranged from 0.3 to 1.3
(Table 1) [11, 19, 24–27].
Six studies, conducted over the past 20 years, reported
increases in hospitalizations over time (Table 1) [13, 15,
16, 18, 21, 22]. A UK study observed an annual increase in
hospitalizations from 2004 (n = 8611) to 2011 (n = 15,885)
of 9% (relative risk [RR] 1.09, 95% confidence interval [CI]
1.08–1.10, p < 0.0001) [16]. Another UK study reported a
crude annual increase of 8% in admissions to the ICU for
bronchiectasis as a primary diagnosis over a period of 5
years from 2009 [15]. The age-adjusted rate of
bronchiectasis-associated hospitalizations also increased
significantly in Germany over a similar period (2005–
2011), from 8.9 to 10.6 per 100,000 population, corre-
sponding to an average annual increase of 2.9% (95% CI
1.7–4.2, p < 0.00001) [21]. Similarly, a US study reported
an annual increase of 1.7% for men and 2.6% for women
for bronchiectasis as a primary diagnosis over a period of
10 years, from 1996 to 2006 [13].
Three studies demonstrated higher rates of hospitalization
with increasing age [13, 20, 21], and four studies reported
higher rates of hospitalization in women compared with
men [13, 18, 20, 21]. For example, in Germany, Ringshausen
et al. [21] observed the highest age-specific rate of
hospitalization (for bronchiectasis as a primary or secondary
diagnosis) of 39.4 per 100,000 population among men aged
75 to 84 years compared with 9.4 per 100,000 for all ages
(overall study population). In a US study based on hospital
discharge records (1993–2006), the annual rate of
bronchiectasis-associated hospitalizations increased dramat-
ically with age for both men and women; this was approxi-
mately 8-fold higher in patients aged 80–84 years compared
with patients aged 55–59 years [13]. Hospitalizations per
100,000 population were also higher in women than men
(20.6 per 100,000 vs 12.3 per 100,000).
Four studies reported a higher incidence of hospitalization
in patients with P. aeruginosa than in patients without this
infection [27, 31–33]. This included a large meta-analysis of
21 studies (performed in Europe, Asia, and Australia) that re-
ported a 6.5-fold increase in hospital admission for patients
with vs without P. aeruginosa (odds ratio [OR] 6.57, 95% CI
3.19–13.51, p < 0.0001) [31]. A further study [9] compared
resource use for the 12months before and following an
index claim for P. aeruginosa in patients with bronchiectasis
(n= 716). Statistically significant increases in the number of
hospital admissions (3 pre- vs 7 post-P. aeruginosa), as well
as ER visits (0.5 vs 1.0), office visits (16.3 vs 27.1), and
pharmacy visits (23.2 vs 36.2), were observed following a
diagnosis of P. aeruginosa infection (p < 0.0001 for all
comparisons). Another study found that patients with
extensive lung damage had a significantly greater risk of re-
admission compared with those with less extensive damage
(p= 0.047) [28].
Another factor contributing to the need for
hospitalization is the frequency of exacerbations. A US
study (2008–2012) which analyzed MarketScan data on
resource use in patients receiving treatment for exacer-
bations (n = 5847) found that the mean (± SD) annual
number of hospital outpatient visits doubled from 10.8
± 15.1 for patients with 1 exacerbation/year to 21.0 ±
22.3 in those with ≥3 exacerbations/year [11]. Similarly,
mean (± SD) hospital length of stay increased from 6.9
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± 9.8 in patients with 1 exacerbation/year to 7.3 ± 6.9
and 9.3 ± 8.6 days, respectively, in patients with 2 and ≥ 3
exacerbations/year. Statistically significant increases in
ER visits and physician office visits were also noted for
patients with more frequent exacerbations (p < 0.0001).
The average length of hospital stay was reported in 12
publications [11, 13–18, 20, 25, 28–30] and ranged from
2 to 17 days. The annual number of exacerbations [11],
the presence of comorbidities [28], and the extent of
lung damage [28] were found to be associated with an
Table 1 Hospitalization rates for bronchiectasis (mean age-adjusted and other rates)
Reference Dates, N Results
Mean annual age-adjusted hospitalization rates
Bibby et al., 2015 [20] (New Zealand) 2008–2013
N = 5494
• 25.7 per 100,000 population (1° diagnosis)
Ringshausen et al., 2013 [21] (Germany) 2005–2011
N = 61,838
• 9.4 per 100,000 population (any diagnosis)
• 1.8 per 100,000 (1° diagnosis)
Sanchez-Munoz et al., 2016 [18] (Spain) 2004–2013
N = 70,676
• 15.5 per 100,000 population (1° diagnosis)
Seitz et al., 2010 [13] (USA) 1996–2006
N = 258,947
• 16.5 per 100,000 population (any diagnosis)
• 2.0 per 100,000 (1° diagnosis)
Hospitalization rates
Chan et al., 2013 [24] (New Zealand) 2001–2008
N = 100
• Mean annual hospitalization rate per patient: 1.29
de Costa et al., 2015 [25] (Portugal) 2013–2014
N = 70
• Mean annual hospitalization rate per patient: 0.8
Hwang et al., 2013 [26] (South Korea) NR
N = 79
• Mean annual hospitalization rate per patient: 0.3
• Mean number of admissions among those who were
admitted: 3.08
de la Rosa et al., 2016 [19] (Spain) 2013
N = 456
• Mean annual hospitalization rate per patient: 0.34 ± 0.9
• Mean annual hospitalization rate increased from 0.14 ± 0.5
per patient for patients with mild bronchiectasis to 1.05 ± 1.6
for those with severe bronchiectasis (p < 0.001)
Germino and Liao, 2016 [11] (USA) 2008–2012
N = 5847
• Mean inpatient visits in first year of follow-up: 0.32 per patient
• A total of 22.2, 24.0, and 34.4% of patients with 1, 2, and 3 or
more exacerbations had an inpatient visit
McDonnell et al., 2015 [27] (UK) 2007–2009
N = 155
• Mean annual hospitalization rate in 143 patients was 0.9 ± 1.6 per
patient with self-reported total number of admissions equal to
131 with 90.8% admissions due to bronchiectasis
Change in hospitalization rates with time
Navaratnam et al., 2014 [16] 2004–2011
NS
• 8611 and 15,885 hospitalizations for bronchiectasis in 2004 and
2011, respectively (1° diagnosis)
• Overall annual increase in hospitalizations of 9% (RR 1.09; 95% CI,
1.08–1.10, p < 0.0001)
Navaratnam et al., 2015 [15] 2009–2013
N = 536
• 74 and 121 admissions to ICU in 2009 and 2013, respectively,
equating to a crude annual increase of 8% (RR 1.08; 95% CI, 1.02–1.15,
p = 0.01) (1° diagnosis)
Ringshausen et al., 2013 [21] 2005–2011
N = 61,838
• 8.9 and 10.6 hospitalizations per 100,000 in 2005 and 2011, respectively –
an average increase of 2.9% (95% CI, 1.7–4.2, p < 0.00001) per year (any
diagnosis)
• 1.6 per 100,000 in 2005 to 1.8 per 100,000 in 2011 (from graph)
(1° diagnosis)
Sanchez-Munoz et al., 2016 [18] (Spain) 2004–2013
N = 70,676
• 16.5 and 17.0 hospitalizations per 100,000 in 2004 and 2013, respectively
(p < 0.001) (1° diagnosis)
Seitz et al., 2010 [13] (USA) 1996–2006
N = 258,947
• Annual percentage change was 2.4% for men and 3.0% for women,
demonstrating an increase in the number of hospitalizations over the
time period assessed (any diagnosis)
• Increase of 1.7% for men and 2.6% for women (1° diagnosis)
Niewiadomska et al., 2016 [22] 2000–2011 • Crude hospitalization rate increased from 2.0 per 100,000 in 2000 to 8.1
per 100,000 in 2011 (1° diagnosis)
1° primary, CI confidence interval, ICU intensive care unit, NR not reported, NS not specified, RR relative risk
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increase in the length of hospitalization. Two other stud-
ies reported that P. aeruginosa infection was associated
with a significantly longer duration of hospitalization
[28, 33].
Costs and cost drivers
Costs for the management of bronchiectasis have been re-
ported in eight studies [9, 10, 12, 14, 18, 19, 34, 35] (see
Table 2). A cost analysis of patients managed in six Span-
ish hospitals, described by de la Rosa et al. 2016 [19], re-
ported a mean annual cost for bronchiectasis (including
both hospital and primary care costs) of €4672 ± 6281 per
patient (cost year 2013), increasing with disease severity
(as measured by FACED score) from €2993 (score 0–2,
i.e., low mortality risk) to €9999 (score 5–7, i.e., high mor-
tality risk) [19]. The overall cost per patient is consistent
with a second Spanish study, which determined the costs
of bronchiectasis based on analysis of the Spanish Na-
tional Hospital Database [18]. The mean annual cost for
2013 was estimated at €3515 for patients with bronchiec-
tasis as a primary diagnosis (n = 70,676) and €4559 for
patients with a secondary diagnosis (n = 211,531). Four
other studies report the annual costs of bronchiectasis in
the USA, which ranged from US$13,244 (cost year 2001)
[14] to US$26,284 (in patients without exacerbation,
2008–2011) [34, 35], US$37,030 (in patients with exacer-
bation, 2008–2011) [34], and US$67,764 (in patients with
P. aeruginosa, 2007–2013). [9]
De la Rosa et al. [19] also reported on the elements
contributing to the management costs for bronchiec-
tasis and factors associated with increased costs.
Overall, bronchodilators, corticosteroids, and short- or
Table 2 Total annual cost per patient for bronchiectasis
Reference Time frame
(cost year)
Annual cost per patient
De la Rosa et al., 2016 [19] (Spain) 2013 (2013) Overall €4672 ± 6281
FACED 0–2: €2993
FACED 3–4: €4732
FACED 5–7: €9999
Sanchez-Munoz et al., 2016 [18] (Spain) 2004–2013 Bronchiectasis 1° diagnosis
2004: €3961
2013: €3515
Time trend: p < 0.001
Bronchiectasis 2° diagnosis
2004: €4327
2013: €4559
Time trend: p < 0.001
Weycker et al., 2005 [14] (USA) 1999–2002
(2001)
Bronchiectasis: US$13,244
Control: US$7563
Incremental cost for bronchiectasis:
US$5681 (95% CI US$4862–6593)
Joish et al., 2013 [12] (USA)a January 2005 to December
2009
Overall incremental cost of bronchiectasis:
US$2319 (95% CI US$1872–2765)
Respiratory-related incremental cost
of bronchiectasis: US$1607 (95% CI
US$1406–1809)
Joish et al., 2013 [34] (USA)a July 2008 to July 2011 Annual cost of bronchiectasis with exacerbation,
US$37,030
Annual cost of bronchiectasis without exacerbation,
US$26,284
Incremental cost, adjusting for baseline expenditure,
US$8120
Incremental hospital costs: US$6147
Joish et al., 2013 [35] (USA)a July 2009 to July 2010 Annual cost of bronchiectasis with exacerbation,
US$35,718
Annual cost of bronchiectasis without exacerbation,
US$26,868
Incremental cost, adjusting for baseline expenditure:
US$7643
Incremental hospital costs: US$5772
Blanchette et al., 2017 [9] (USA)b 2007–2013 Total healthcare cost per patient:
For year before P. aeruginosa diagnosis: US$36,213
For year after P. aeruginosa diagnosis: US$67,764
Incremental cost: US$31,551
Blanchette et al., 2016 [10] (USA)b 2007–2013 Adjusted total cost
Incremental increase in patients with P. aeruginosa:
US$56,499
Incremental hospital costs: US$41,972
CI confidence interval
aBased on data from the MarketScan claims database
bBased on data from the PharMetrics Plus administrative claims database
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long-acting anticholinergics accounted for the largest
proportion of total costs (46%). However, as these agents
are not recommended for bronchiectasis, these costs may
relate to the management of comorbidities such as
chronic obstructive pulmonary disease (COPD), or in-
appropriate use in patients with bronchiectasis. Exacerba-
tions (23%), inhaled antibiotics (18%), and admissions
(13%) accounted for the remainder of the total costs. In
patients with a high FACED score (i.e., greater risk of
mortality), exacerbations accounted for the greatest pro-
portion of the total costs (34%) whereas in patients with a
low FACED score, exacerbations accounted for only 18.5%
of the total costs (Fig. 2). Similar differences across the
three severity cohorts were observed for the proportion of
costs relating to inhaled antibiotics and admissions. In
contrast, inhalers (long-acting beta-agonists, inhaled corti-
costeroids, and short- or long-acting anticholinergics)
accounted for 54.5% of total costs for patients with a low
FACED score compared with 27.0% of total costs for pa-
tients with a high FACED score (Fig. 2). Hence, the costs
of managing exacerbations increased dramatically in pa-
tients with severe disease (from €769, FACED score 0–2
to €4305, FACED score 5–7). Total annual costs were
higher in patients experiencing > 2 exacerbations per year
compared to ≤2 exacerbations (€7520 vs €3892, respect-
ively), and in patients with versus without COPD (€7448
vs €4168, respectively). However, patients experiencing > 2
exacerbations a year, or having severe disease, accounted
for only approximately 20% of the total population. There-
fore, this study found that a disproportionately large pro-
portion of the cost of bronchiectasis relates to
management of patients with severe disease.
Other studies have also reported that managing exac-
erbations is a significant cost driver. Two US studies re-
ported an incremental increase in annual overall costs
for patients with exacerbations of US$8120 and
US$7643 [34, 35]. Two further US studies report an in-
crease in costs for patients with P. aeruginosa infection
of US$41,972 and US$31,551. [9, 10]
Discussion
The published literature suggests that hospitalization
costs constitute a major economic burden associated
with bronchiectasis, especially in patients who experi-
ence frequent exacerbations. This is reflected in the re-
sults of several studies analyzing data from US claims
databases for patients with bronchiectasis [9, 10, 14].
Consistent with this, an assessment of hospitalization
rates and lengths of hospitalization, based on US claims,
has shown an increase in resource use with frequency of
exacerbations [11]. In addition, two economic assess-
ments have reported an increase in annual overall costs
Fig. 2 Distribution of costs in patients with bronchiectasis according to disease severity. Analysis of data from six hospitals (n = 456). Severity was
assessed according to the FACED score: mild, 0–2 (i.e. low mortality risk); moderate, 3–4; and severe, 5–7 (i.e. high mortality risk)Inhalers included
long-acting beta-agonists, inhaled corticoids and short- or long-acting anticholinergics. Adapted from de la Rosa et al., 2016 [19]
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of approximately US$8000 for patients experiencing ex-
acerbations compared with those without exacerbations
[34, 35]. While data for Europe and the US cannot be
compared directly given the difference in currency and
the cost years of the different studies, comparison of
the annual costs reported for Spain [18, 19] (€4000 in
2013, corresponding to approximately US$5000 at
current exchange rates) and the USA [34, 35]
(US$26,000 to 35,000 for 2007–2013) suggest that costs
are considerably higher in the USA. This may reflect
higher rates of hospitalization in the USA but also dif-
ferences in design between the studies. However, clin-
ical experience clearly indicates that hospitalization for
the treatment of exacerbations merely represents part
of the management of patients with bronchiectasis.
Hence, the true economic burden of bronchiectasis is
not well reflected when only hospitalization or associ-
ated resource use is taken into consideration. While
hospitalization plays an important role in the manage-
ment of exacerbations, most patients require ongoing
treatment for symptoms throughout the course of their
disease, much of which is given in primary care. Fur-
thermore, the introduction of new treatments that im-
prove the management of bronchiectasis may reduce
not only the need for hospitalization but also care in
outpatient and primary care settings.
In addition to demonstrating the contribution of
hospitalization to the overall costs of managing bronchi-
ectasis, the identified studies showed that costs increase
with the severity of disease and are higher in patients
with P. aeruginosa. This is consistent with the observa-
tion that such patients are sicker and, independently of
other factors, have increased hospitalizations [36] – the
major driver of healthcare costs – and worse quality of
life. Therefore, the evidence supports a conclusion that
P. aeruginosa itself is a driver of increased healthcare
costs. The increased costs associated with disease sever-
ity and P. aeruginosa infection emphasize the import-
ance to the healthcare system of improving management
of these patients. Current management for bronchiectasis
patients is suboptimal compared with guideline recom-
mendations [6] as illustrated in one study [37]. From a
healthcare system perspective, initiatives to improve qual-
ity and cost-effectiveness of care require first an under-
standing of the burden of disease and associated costs.
The predominance of hospitalization and related re-
source use in the economic burden of bronchiectasis ac-
cording to the published literature may reflect the types
of studies and the information available from retrospect-
ive analyses. This may incompletely reflect many aspects
of the economic burden of bronchiectasis, such as costs
and resource use in primary care. Even the most compre-
hensive study identified in this review [19] may have over-
emphasized the role of hospital-based treatments because
the cohort was based on patients attending specialist hos-
pital clinics and not regular outpatient settings.
These retrospective studies rely on accurate recording
of a bronchiectasis diagnosis in patient records or
claims, e.g., using the ICD-9-CM codes. Similarities be-
tween bronchiectasis-related symptoms and other better
recognized respiratory diseases, such as COPD and
asthma, and greater availability of treatments for these
respiratory conditions, can lead clinicians to miscode
bronchiectasis. Therefore, using patient records or
claims are likely to underestimate the real prevalence of
bronchiectasis and the associated resource use.
A more accurate evaluation of the burden of bronchi-
ectasis should take into account both the substantial im-
pact of bronchiectasis on patients and the costs and
resource use involved in treating patients across the
whole spectrum of the disease. Indirect and intangible
costs associated with bronchiectasis are likely to include
the impact of ongoing symptoms and exacerbations on
patient HRQoL and well-being. These costs should be
considered both in the early stages of disease and
through the changes to advanced disease. While the im-
pact of bronchiectasis on HRQoL and well-being has
been documented, [38–42] other intangible costs have
not been studied. For example, the impact of ongoing
symptoms on work productivity should be further ex-
plored. Clinical experience indicates that some patients
have to reduce their working hours, or take early retire-
ment, while others may be less productive because of
the effects of symptoms. However, absenteeism, a reduc-
tion in working hours, or early retirement are difficult to
estimate in patients, their families, and caregivers. To
our knowledge, these aspects have not been analyzed, or
reported. Furthermore, physiotherapy and regular airway
clearance may require substantial time investment from
patients on a daily basis. Other costs that may arise from
severe disease include adaptations to the house, or the
need to move into a nursing home, but evidence for
such indirect and intangible costs has not been system-
atically reported.
In addition to the indirect and intangible costs of
bronchiectasis, clinical experience clearly indicates
that bronchiectasis is associated with extensive direct
medical costs that go far beyond those documented
in the publications identified in this review. For in-
stance, from our sample of studies, we observed that
costs for diagnostic tests, or the extensive range of
interventions and monitoring, often initiated in pri-
mary care (e.g., physiotherapy, pulmonary rehabilita-
tion, and sputum microbiology), have not been
reported. Costs related to secondary care have also
been omitted, such as providing home intravenous
and nebulized antibiotic therapies, nutritional inter-
ventions, and radiologic assessments [1, 3–5]. Social
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care is also an important part of patient management
and should also be studied. Advanced disease may ne-
cessitate home oxygen therapy, regular hospital ad-
missions, and other costly interventions, such as lung
transplantation [1, 3–5]. Self-payment costs for med-
ical treatments and procedures could be substantial
and have been reported by patients from several
countries. However, these costs are not well docu-
mented or reported.
Conclusions
The results of this systematic review indicate that the
costs of management of bronchiectasis are substantial
and are likely to be underestimated in the current
published literature. Most studies are specific to the
US healthcare landscape and have focused on the
management of exacerbations. Only two studies
reported the economic burden of bronchiectasis in
Europe, namely in Spain. Assessing the burden of
bronchiectasis is complex given the wide range of in-
terventions used across different settings and across
the spectrum of disease severity, together with the
impact of comorbidities, such as anxiety, depression,
cardiovascular disease and other respiratory diseases.
More accurate assessments are needed to ensure ap-
propriate allocation of resources to enable patients to
receive optimal care and to enable accurate assess-
ment of the cost-effectiveness of new interventions.
Such assessments need to take into account the full
spectrum of interventions and their roles across the
clinical pathway for the management of bronchiec-
tasis, and the impact of symptoms and treatments on
the HRQoL and productivity of patients and carers.
For this reason, as outlined in Fig. 3, we propose a concep-
tual framework that could be used for future research, in-
cluding prospective and retrospective observational studies,
and economic models to facilitate the comprehensive esti-
mation of the burden and impact of bronchiectasis in differ-
ent healthcare settings. While the treatment pathway is
largely comparable in most developed countries, differences
will remain regarding the settings and costs of interventions.
Evaluations in different countries may therefore be necessary.
Considering patients across the whole disease spectrum, the
impact of comorbidities, and the impact of bronchiectasis on
other conditions will also be important to comprehensively
map the economic burden of bronchiectasis.
Fig. 3 Conceptual framework for assessment of the economic burden of bronchiectasis. BMI body mass index, ER emergency room, FEV forced
expiratory volume, HRCT high-resolution computed tomography, HRQoL health-related quality of life, ICU intensive care unit, IV intravenous, NIV
non-invasive ventilation
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